Advanced Biomed (ADVB) Stock Price & Analysis Today

ADVB

(NASDAQ)

Advanced Biomed Inc.

$4.55-- (--)

Loading... - Market loading

Overview Financials Forecast Statistics Dividends Historical Profile

Advanced Biomed Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$4.18 - $4.55

52-Week High$9.88

52-Week Low$0.34

Open$4.18

Volume2.94K

Average Volume (3M)2.94K

Market Cap98.46M

Shares Outstanding21.64M

P/E Ratio (TTM)19.06

Price to Book (P/B)10.18

EV/EBITDA-65.30

50-Day MA$4.83

200-Day MA$2.95

52-Week Change16.51%

Annual Dividend$0.00

Dividend Yield0.00%

Payout Ratio0.00%

Day's Range$4.18 - $4.55

52-Week High$9.88

52-Week Low$0.34

Open$4.18

Volume2.94K

Average Volume (3M)2.94K

Market Cap98.46M

Shares Outstanding21.64M

P/E Ratio (TTM)19.06

Price to Book (P/B)10.18

EV/EBITDA-65.30

50-Day MA$4.83

200-Day MA$2.95

52-Week Change16.51%

Annual Dividend$0.00

Dividend Yield0.00%

Payout Ratio0.00%

About Advanced Biomed

Company overview, fundamentals, and corporate profile

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan.Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients.In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies.Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People’s Republic of China.The company was founded in 2014 and is headquartered in New York, New York.

Frequently Asked Questions About Advanced Biomed

What is the current stock price for ADVB?

As of the latest trading session, ADVB stock trades at $4.55. The 52-week range is $0.34–$9.88, with a day range of $4.18–$4.55.

What is the P/E ratio for ADVB?

Advanced Biomed's trailing P/E ratio is 19.1, meaning investors pay $19.1 for every $1 of annual earnings. Advanced Biomed operates in the Healthcare sector.

Does ADVB pay dividends?

Advanced Biomed does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for ADVB?

Analyst ratings and recommendations for ADVB are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.

What is the market cap of ADVB?

Advanced Biomed's market capitalization is $98.5M, classifying it as a micro-cap company. Advanced Biomed operates in the Healthcare sector within the Diagnostics & Research industry.

Advanced Biomed (ADVB) Stock Price & Financial Analysis

Advanced Biomed Stock Price Chart

Price Chart

Financial Metrics & Key Statistics

Frequently Asked Questions About Advanced Biomed